Therma Bright Announces up to $420,000 Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - October 23, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, announces that it proposes to undertake a non-brokered private placement of up to 14,000,000 common shares (the "Shares") at a price of $0.03/Share for total proceeds of up to $420,000 (the "Offering"). In accordance with the policies
Technology, Biotechnology, Health
2026-10-23 8:37 PM EDT | Therma Bright Inc.
Defence Therapeutics Announces Convertible Debenture Interest Payment
Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® drug-delivery platform, is pleased to announce convertible debentures interest payment in common shares of the Company. The Company announces that, in accordance with the terms and condi
Biotechnology, Pharmaceuticals, Health
2026-10-23 4:15 PM EDT | Defence Therapeutics Inc.
Global Hemp Group Appoints Mickey Goldstein as Chief Financial Officer, Appoints Davidson & Company as Auditor
Vancouver, British Columbia--(Newsfile Corp. - October 23, 2026) - Global Hemp Group Inc. (CSE: GHG) (FSE: GHG0) (OTC PINK: GBHPF) ("GHG" or the "Company") is pleased to announce the appointment of Mickey Goldstein, CPA, CA, as Chief Financial Officer, effective immediately. Ms. Goldstein succeeds Christopher Cherry. Ms. Goldstein is Director, Accounting Advisory at Crowe MacKay LLP, where she provides strategic financial and advisory services to priv
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Cannabis
2026-10-23 9:59 AM EDT | Global Hemp Group Inc.
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased announce that, further to its news release dated September 28, 2026, it has closed an initial tranche (the "Initial Tranche") of its previously announced $600,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 5,200,000 units
Biotechnology, Pharmaceuticals, Health
2026-10-22 5:24 PM EDT | PreveCeutical Medical Inc.
Envoy Medical Announces Reverse Stock Split
White Bear Lake, Minnesota--(Newsfile Corp. - October 22, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fully implanted hearing solutions, today announced that it will implement a 1-for-10 reverse stock split of its outstanding shares of Class A common stock ("Common Stock"), effective at 12:01 a.m. Eastern Time on October 26, 2026 (the
Biotechnology, Healthcare and Hospitals
2026-10-22 8:30 AM EDT | Envoy Medical, Inc.
Envoy Medical Hits Six-Month Milestone, Marks Halfway Point in Final Stage of Data Collection, and Highlights Differentiated Device Design
White Bear Lake, Minnesota--(Newsfile Corp. - October 20, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("En
Biotechnology, Healthcare and Hospitals
2026-10-20 8:30 AM EDT | Envoy Medical, Inc.
TempraMed Announces LIFE Offering up to C$8 Million to Accelerate Global Expansion and Fulfilment of Forecasted Demand
Recent Highlights: Record sales: July 2026 sales were about US$522K1, the best month in the company's history, and August was about US$403K, its second-best. Run rate revenue of ~US$5.5M Sales for the first eight months of 2026 were about US$2.07M, already above the US$1.8M booked for all of 2025. Growing patent portfolio: 4 new global patents granted in 2026, for a total of Global distribut
Technology, Biotechnology, Pharmaceuticals, Health
2026-10-20 7:00 AM EDT | TempraMed Technologies Ltd.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA therapeutic platform, including its lead clinical ca
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-19 9:53 AM EDT | Phio Pharmaceuticals Corp.
OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million
Grasonville, Maryland--(Newsfile Corp. - October 19,
2026-10-19 8:30 AM EDT | OS Therapies
CBIH Announces Expanded Research Strategy at the Intersection of Endocannabinoid Science and Biological Medicine
Houston, Texas--(Newsfile Corp. - October 19, 2026) - Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced an expansion of its scientific research strategy focused on the intersection of endocannabinoid biology, precision medicine, and the development of intellectual property with potential biomedical applications. "We are witnessing a new era in the history of medicine: an era in which hum
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-10-19 7:00 AM EDT | Cannabis Bioscience International Holdings
Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform
Montreal, Quebec--(Newsfile Corp. - October 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® drug-delivery platform, is pleased to announce two significant achievements at World ADC San Diego 2026, held October 12-15: winning the conference's Best Poster Award for its Accum&#
Biotechnology, Pharmaceuticals, Health
2026-10-19 3:15 AM EDT | Defence Therapeutics Inc.
TempraMed Enters into Exclusive Kuwait Distribution Agreement, Expanding Gulf Region Commercial Footprint
Toronto, Ontario--(Newsfile Corp. - October 15, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has executed a definitive exclusive distribution agreement dated September 14, 2026 (the "Distribution Agreement") with OGM For Import Medicine and Medical Supplies (the "Distributor
Technology, Biotechnology, Pharmaceuticals, Health
2026-10-15 3:05 AM EDT | TempraMed Technologies Ltd.
Biosenta Commences TRUE(TM) Testing with Dynamic Facility Services
Calgary, Alberta--(Newsfile Corp. - October 13, 2026) - Biosenta Inc. (CSE: ZRO) ("Biosenta" or the "Company") announces that it has commenced testing of its TRUE™ disinfectant with Dynamic Facility Services Ltd. ("Dynamic"), advancing the commercial pilot program previously announced on September 1, 2026. TRUE™ has now been deployed at two locations serviced by Dynamic - an office building and a commercial operation - to evaluate defined applications under real-world operat
Biotechnology, Chemical, Household / Consumer / Cosmetics
2026-10-13 10:59 PM EDT | Biosenta Inc.
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), representing a critical operational and strategic milestone as the Company advances PH-762 to the next
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-13 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing Opportunity
Botanical Synthesis™-developed asset has now completed development, commercial-scale manufacturing and the applicable self-affirmed GRAS process and is ready for production at BioHarvest's GMP facility Milestone demonstrates BioHarvest's ability to create proprietary plant-derived assets and advance them from plant-cell development through industrial manufacturing and commercialization High-potency proprietary olive-derived Verbascoside composition demonstra
Biotechnology, Pharmaceuticals, Health
2026-10-13 7:00 AM EDT | BioHarvest Sciences Inc.
Envoy Medical Submits Second Module of Modular Premarket Approval Application to FDA for Breakthrough Designated Acclaim(R) Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - October 12, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health and neuroprosthetics company pioneering fu
Biotechnology, Healthcare and Hospitals
2026-10-12 8:30 AM EDT | Envoy Medical, Inc.
Theralase(R) to Present at ThinkEquity Conference
Toronto, Ontario--(Newsfile Corp. - October 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of proprietary Energy-Activated Small Molecules ("EASMs") for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the Company has been invited to present at the 2026 Thin
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-10-09 7:00 AM EDT | Theralase Technologies Inc.
Entheon Announces Continuance into British Columbia
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Entheon Biomedical Corp. (CSE: ENBI.X) (OTCID: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has continued out of the jurisdiction of Canada under the Canada Business Corporations Act into the provincial jurisdiction of British Columbia under the Business Corporations Act (British Columbia) (the "BCBCA"). Shareholders approved the continuance at the Company's an
Biotechnology, Cannabis, Psychedelics, Cannabis Ancillary Service Provider
2026-10-08 6:49 PM EDT | Entheon Biomedical Corp.
TMC Group Reports Progress on Capacity Expansion Ahead of EANM 2026
Vancouver, British Columbia--(Newsfile Corp. - October 8, 2026) - Earlier this year, TMC Group, a Canadian manufacturer of enriched stable isotopes, announced plans to increase production capacity by 50 percent. Today, the company is commissioning new production lines that are already producing material, marking an early milestone in that work. The company will be exhibiting at the European Association of Nuclear Medicine (EANM) Annual Congress in Vienna next week, where the team will c
Technology, Biotechnology, Chemical, Pharmaceuticals
2026-10-08 12:00 PM EDT | TMC Group
Enoumena Therapeutics and AOP Health Announce Exclusive Canadian Commercialization Agreement for SIBBORAN(R) (landiolol)
Quebec and Vienna, Austria--(Newsfile Corp. - October 8, 2026) - Enoumena Therapeutics Inc. and AOP Health today announced an exclusive commercialization agreement to expand Canadian institutional access to PrSIBBORAN® (landiolol hydrochloride), an ultra-short-acting, selective beta-1 adrenergic receptor blocker. Authorized by Health Canada in 2023, SIBBORAN is indicated for the short-term reduction of ventricular rate in patients with supraventricular tachycar
Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-10-08 10:47 AM EDT | Enoumena Therapeutics Inc.